Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Women presenting with overactive bladder symptoms will be randomized to one of 3 arms
(anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing,
functional MRI of the brain. Cognitive testing and functional MRI will be repeated after
taking their double blinded intervention for 30 days.
Phase:
Phase 4
Details
Lead Sponsor:
Baylor Research Institute
Collaborators:
International Urogynecological Association The Methodist Hospital Research Institute The Methodist Hospital System